Comparison of Rates of Progression of Macular OCT Measures in Glaucoma.

OCT, progression full macular thickness ganglion cell complex ganglion cell layer ganglion cell/inner plexiform layer macular sectors rates of change

Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
06 2020
Historique:
received: 10 12 2019
accepted: 05 04 2020
entrez: 25 8 2020
pubmed: 25 8 2020
medline: 25 8 2020
Statut: epublish

Résumé

The purpose of this study was to compare rates of change of various macular thickness measures and evaluate the influence of baseline damage on macular rates of change. One hundred twelve eyes (112 patients) with ≥ 2 years of follow-up and ≥ 5 macular optical coherence tomography (OCT) images and 10-2 visual field (VF) tests were included. OCT measures of interests were full macular thickness (FMT), ganglion cell complex (GCC), ganglion cell/inner plexiform layer (GCIPL), ganglion cell layer (GCL), and outer retinal layer (ORL) thickness in 3° × 3° superpixels. Rates of change were estimated with linear regression and normalized by dividing rates by the average normative superpixel thickness. We compared rates of change and proportion of significantly worsening superpixels (detection rate) and improving superpixels (false discovery rate [FDR]) among macular measures as a function of baseline thickness and 10-2 VF status. Median (interquartile range [IQR]) baseline VF mean deviation, follow-up time, and number of VFs/OCTs were -7.6 dB (-11.8 to -3.8 dB), 4.5 years (4.0-5.0 years), and 9 (8-10), respectively. Normalized FMT and GCC rates of change were faster and detection rates were higher than GCIPL and GCL ( GCC measurements are most likely to detect structural worsening along the spectrum of glaucoma severity. Although FMT rates of change are least influenced by baseline thickness, they partially reflect likely age-related ORL changes. GCC thickness measurements seem to be the optimal macular outcome measure for detection of glaucoma deterioration.

Identifiants

pubmed: 32832255
doi: 10.1167/tvst.9.7.50
pii: TVST-19-2167
pmc: PMC7414740
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Pagination

50

Subventions

Organisme : NEI NIH HHS
ID : R01 EY029792
Pays : United States

Informations de copyright

Copyright 2020 The Authors.

Déclaration de conflit d'intérêts

Disclosure: A. Rabiolo, Santen Italy srl; V. Mohammadzadeh, None; N. Fatehi, None; E. Morales, None; A.L. Coleman, None; S.K. Law, None; J. Caprioli, Aerie, Alcon, Allergan, Glaukos, New World Medical; K. Nouri-Mahdavi, Heidelberg Engineering, Aerie

Références

J Glaucoma. 2016 Apr;25(4):383-9
pubmed: 25580890
Ophthalmology. 2017 Aug;124(8):1218-1228
pubmed: 28461015
Arch Ophthalmol. 2011 Dec;129(12):1529-36
pubmed: 22159673
Acta Ophthalmol. 2013 Mar;91(2):e86-91
pubmed: 23356423
Ophthalmology. 2011 Dec;118(12):2403-8
pubmed: 21907415
Br J Ophthalmol. 2015 Jun;99(6):732-7
pubmed: 25492547
PLoS One. 2018 Apr 19;13(4):e0196112
pubmed: 29672563
Ophthalmology. 2014 Mar;121(3):741-9
pubmed: 24290806
Transl Vis Sci Technol. 2019 Sep 11;8(5):2
pubmed: 31555493
Transl Vis Sci Technol. 2016 Jul 19;5(4):5
pubmed: 27486555
Invest Ophthalmol Vis Sci. 2013 Jul 22;54(7):4934-40
pubmed: 23761080
Am J Ophthalmol. 2017 Feb;174:1-8
pubmed: 27818206
Ophthalmology. 2017 Oct;124(10):1466-1474
pubmed: 28549518
Acta Ophthalmol. 2019 Mar;97(2):e207-e215
pubmed: 30338652
Invest Ophthalmol Vis Sci. 2012 Sep 06;53(10):5985-90
pubmed: 22879418
Am J Ophthalmol. 2009 Jan;147(1):39-44.e1
pubmed: 18790472
Ophthalmology. 2013 Dec;120(12):2485-2492
pubmed: 23993360
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4815-23
pubmed: 27623336
Vision Res. 2007 Oct;47(22):2901-11
pubmed: 17320143
Br J Ophthalmol. 2019 Sep;103(9):1217-1222
pubmed: 30385436
Invest Ophthalmol Vis Sci. 2012 Jun 20;53(7):3817-26
pubmed: 22562510
PLoS One. 2018 Mar 9;13(3):e0194169
pubmed: 29522565
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4857-64
pubmed: 25829417
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT511-8
pubmed: 27454660
Am J Ophthalmol. 2015 Mar;159(3):565-76.e2
pubmed: 25498118
Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3662-8
pubmed: 17652736
J Glaucoma. 2017 Mar;26(3):208-215
pubmed: 27811573
Transl Vis Sci Technol. 2016 Mar 4;5(2):1
pubmed: 26966637
Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3413-8
pubmed: 21357406
Sci Rep. 2018 Jul 23;8(1):11037
pubmed: 30038425
Surv Ophthalmol. 2016 Sep-Oct;61(5):597-615
pubmed: 27018149
Ophthalmology. 2018 Dec;125(12):1907-1912
pubmed: 29934267
Br J Ophthalmol. 2014 Mar;98(3):322-8
pubmed: 24307717
Can J Ophthalmol. 2017 Aug;52(4):355-360
pubmed: 28774516
BMC Ophthalmol. 2018 Jul 11;18(1):169
pubmed: 29996804

Auteurs

Alessandro Rabiolo (A)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Ophthalmology, University Vita-Salute, IRCCS San Raffaele, Milan, Italy.

Vahid Mohammadzadeh (V)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Nima Fatehi (N)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Esteban Morales (E)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Anne L Coleman (AL)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Simon K Law (SK)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Joseph Caprioli (J)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Kouros Nouri-Mahdavi (K)

Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH